Mochida Pharmaceutical Co., Ltd. (FRA:MFY)

Market Cap	600.72M -10.2%
Revenue (ttm)	637.91M +11.2%
Net Income	43.11M +39.0%
EPS	1.22 +39.0%
Shares Out	n/a
PE Ratio	13.94
Forward PE	n/a
Dividend	0.45 (2.62%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Open	16.70
Previous Close	17.00
Day's Range	16.70 - 16.70
52-Week Range	16.20 - 21.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About Mochida Pharmaceutical

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and p...

• Industry: Pharmaceutical Preparations
• Founded: 1913
• Employees: 1,508
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MFY

Financial Performance

In fiscal year 2026, Mochida Pharmaceutical's revenue was 116.95 billion, an increase of 11.21% compared to the previous year's 105.16 billion. Earnings were 7.90 billion, an increase of 39.01%.

Financial numbers in JPY